<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119379</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AI060484-01A2B</org_study_id>
    <secondary_id>R01AI060484</secondary_id>
    <nct_id>NCT00119379</nct_id>
  </id_info>
  <brief_title>Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults</brief_title>
  <official_title>Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV lipoatrophy is a condition marked by fat loss; it occurs in many patients taking
      antiretroviral (ARV) therapy that includes nucleoside reverse transcriptase inhibitors
      (NRTIs). Lipoatrophy may be related to mitochondrial toxicity, a condition that can damage
      the heart, nerves, muscles, kidneys, and liver, and can affect the body's ability to produce
      energy. NucleomaxX is a food supplement consisting of a sugar cane extract high in
      nucleosides, which are building blocks that may counteract the negative effects of NRTIs.
      Tenofovir disoproxil fumarate (TDF) is an NRTI that may cause less lipoatrophy than other
      drugs in its class, such as zidovudine (ZDV) or stavudine (d4T). The purpose of this study is
      to determine whether nucleoside supplementation with NucleomaxX and substitution of TDF for
      ZDV or d4T in an ARV regimen can reverse fat loss caused by mitochondrial toxicity in HIV
      infected adults.

      Study hypotheses: 1) The substitution of TDF for d4T or ZDV in patients with HIV lipoatrophy
      will result in an increase in mitochondrial DNA content in fat, skeletal muscle, and
      peripheral blood mononuclear cells (PBMCs), which in turn will lead to an improvement in
      mitochondrial function as assessed by electron transport chain (ETC) and oxidative
      phosphorylation pathway (OXPHOS) activity. The latter should lead to a decrease in fat
      apoptosis and in mitochondrial and lipid oxidative damage biomarkers. 2) Supplementation with
      uridine (via NucleomaxX) will increase mtDNA content in adipose tissue and increase body fat
      content.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NRTIs are an important part of many ARV regimens used to treat HIV infected patients;
      however, the relationship between NRTI-induced mitochondrial dysfunction and lipoatrophy is
      still unclear and requires additional research. Additionally, the relationship between the
      gain in dual-energy x-ray absorptiometry (DEXA)-measured limb fat and mitochondrial DNA
      (mtDNA) content, mitochondrial function, fat apoptosis, and oxidative damage will also be
      examined in this study.

      Patients will participate in this study for 48 weeks. Participants will be randomly assigned
      to one of two groups. Group 1 patients will receive NucleomaxX every other day. Group 2
      patients will substitute TDF for ZDV or d4T every day in their current stable NRTI-containing
      ARV regimen. NucleomaxX will be provided to Group 1 patients, but TDF or any other ARV will
      not be provided by this study.

      There will be 10 study visits, which will occur at study entry and Weeks 2, 4, 8, 12, 18, 24,
      30, 36, and 48. Blood collection will occur at all visits. Additionally, urine collection,
      DEXA scans, and fat biopsies will be done at study entry and Weeks 24 and 48.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fat mtDNA Content</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Subcutaneous abdominal fat mitochondrial DNA (mtDNA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PBMC mtDNA</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA), measured in copies/cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Limb Fat</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change in limb fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trunk Fat</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change in trunk fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lumbar Spine Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change in lumbar spine bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hip Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change in hip bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Infections</condition>
  <condition>Lipodystrophy</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Nutrition Disorders</condition>
  <arm_group>
    <arm_group_label>uridine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NucleomaxX 36 grams TID every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Switch of AZT or d4T to Tenofovir Disoproxil Fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NucleomaxX</intervention_name>
    <description>NucleomaxX 36 grams TID every other day</description>
    <arm_group_label>uridine supplementation</arm_group_label>
    <other_name>uridine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate</description>
    <arm_group_label>Switch to Tenofovir</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HIV lipoatrophy

          -  Receiving a stable stavudine- or zidovudine-containing ARV regimen

          -  HIV-1 RNA viral load less than 50 copies/ml

        Exclusion Criteria:

          -  Coagulopathies or other bleeding disorders

          -  Diabetes requiring medication

          -  Creatinine clearance less than 50 ml/min

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace A. McComsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/22293126/</url>
    <description>click here for more information about uridine supplementation or switch to tenofovir.</description>
  </link>
  <results_reference>
    <citation>McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr. 2008 Aug;62(8):1031-7. Epub 2007 May 30.</citation>
    <PMID>17538545</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <results_first_submitted>December 8, 2016</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Case Western Reserve University</investigator_affiliation>
    <investigator_full_name>Grace McComsey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lipoatrophy</keyword>
  <keyword>mitochondria</keyword>
  <keyword>HIV</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Uridine Supplementation</title>
          <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
        </group>
        <group group_id="P2">
          <title>Switch to TDF</title>
          <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Uridine Supplementation</title>
          <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
        </group>
        <group group_id="B2">
          <title>Switch to TDF</title>
          <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="41" upper_limit="51"/>
                    <measurement group_id="B2" value="48" lower_limit="43" upper_limit="51"/>
                    <measurement group_id="B3" value="48" lower_limit="41" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fat mtDNA Content</title>
        <description>Subcutaneous abdominal fat mitochondrial DNA (mtDNA)</description>
        <time_frame>Baseline to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Uridine Supplementation</title>
            <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
          </group>
          <group group_id="O2">
            <title>Switch to TDF</title>
            <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat mtDNA Content</title>
          <description>Subcutaneous abdominal fat mitochondrial DNA (mtDNA)</description>
          <units>copies/cell</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169" lower_limit="-778" upper_limit="64"/>
                    <measurement group_id="O2" value="321" lower_limit="-298" upper_limit="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in PBMC mtDNA</title>
        <description>Peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA), measured in copies/cell</description>
        <time_frame>Baseline to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Uridine Supplementation</title>
            <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
          </group>
          <group group_id="O2">
            <title>Switch to TDF</title>
            <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PBMC mtDNA</title>
          <description>Peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA), measured in copies/cell</description>
          <units>copies/cell</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24" lower_limit="-158" upper_limit="91"/>
                    <measurement group_id="O2" value="-52" lower_limit="-105" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Limb Fat</title>
        <description>Change in limb fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
        <time_frame>Baseline to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Uridine Supplementation</title>
            <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
          </group>
          <group group_id="O2">
            <title>Switch to TDF</title>
            <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Limb Fat</title>
          <description>Change in limb fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
          <units>limb fat (kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.03" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-0.06" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trunk Fat</title>
        <description>Change in trunk fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
        <time_frame>Baseline to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Uridine Supplementation</title>
            <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
          </group>
          <group group_id="O2">
            <title>Switch to TDF</title>
            <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trunk Fat</title>
          <description>Change in trunk fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
          <units>trunk fat (kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.5" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-0.04" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lumbar Spine Bone Mineral Density (BMD)</title>
        <description>Change in lumbar spine bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
        <time_frame>Baseline to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Uridine Supplementation</title>
            <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
          </group>
          <group group_id="O2">
            <title>Switch to TDF</title>
            <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine Bone Mineral Density (BMD)</title>
          <description>Change in lumbar spine bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
          <units>lumbar spine BMD, g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="-0.96" upper_limit="1.68"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2.9" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hip Bone Mineral Density (BMD)</title>
        <description>Change in hip bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
        <time_frame>Baseline to Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Uridine Supplementation</title>
            <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
          </group>
          <group group_id="O2">
            <title>Switch to TDF</title>
            <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hip Bone Mineral Density (BMD)</title>
          <description>Change in hip bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan</description>
          <units>hip BMD, g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="-0.27" upper_limit="3.56"/>
                    <measurement group_id="O2" value="-3.3" lower_limit="-5.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 4,8,12,18 and 36</time_frame>
      <desc>Study evaluation was conducted at study entry and week 48; and additional safety visits were carried out at weeks 4,8,12,18 and 36 for the purpose of clinical and laboratory monitoring for toxicities, intolerance and adherance.</desc>
      <group_list>
        <group group_id="E1">
          <title>Uridine Supplementation</title>
          <description>NucleomaxX 36 grams TID every other day
NucleomaxX: NucleomaxX 36 grams TID every other day</description>
        </group>
        <group group_id="E2">
          <title>Switch to TDF</title>
          <description>Switch of AZT or d4T to tenofovir
Tenofovir disoproxil fumarate: Switch thymidine NRTI to tenofovir</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolem Gr. 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Gr. 3</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis Gr. 3</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea Gr. 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal phos. Gr. 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal calculus Gr. 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypertrigliceridemia Gr. 3 &amp; 4</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal AST Gr. 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia Gr. 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated CK Gr. 3 &amp; 4</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria Gr. 3</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Incisional hematoma Gr. 1 &amp; 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurtropenia Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gross hematuria Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion left eye - Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarhhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash/Bactrim allergy Gr. 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infected Incisional hematoma Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Incisional seroma Gr. 1 &amp; 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia Gr. 2</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Elevated triglycerides Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Elevated AST Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Prob. Herpes simplex Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Elevated CK Gr. 2</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes zoster Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Incisional neuritis Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal ALT Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal BMD/T score Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal creatine Gr. 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal FBS Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Elevated LFTs Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia Gr. 1 &amp; 2</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoglycemia Gr. 1 &amp; 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal Glucose Gr. 1 &amp; 2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prob. Renal calculus Gr. 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis Gr. 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>URI Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal LDL Chol Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abnormal cholesterol Gr. 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size; Lack of control arm where tNRTI therapy was continued without any intervention; Adherence measured by sachet/pill count method.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Grace McComsey</name_or_title>
      <organization>University Hospitals Case Medical Center</organization>
      <phone>216-844-2739</phone>
      <email>mccomsey.grace@clevelandactu.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

